Nelipepimut S companion diagnostic - Sellas Life Sciences Group/Leica

Drug Profile

Nelipepimut S companion diagnostic - Sellas Life Sciences Group/Leica

Alternative Names: E75 companion diagnostic - Sellas Life Sciences Group/Leica; NueVax™ companion diagnostic - Sellas Life Sciences Group/Leica

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galena Biopharma; Leica Biosystems
  • Developer Leica Biosystems; Sellas Life Sciences Group
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 29 Dec 2017 Galena Biopharma merged with Sellas Life Sciences and subsequently changed its name to Sellas Life Sciences Group
  • 05 Jun 2015 Phase-III development is ongoing in USA, Canada and Europe
  • 05 Dec 2012 Phase-III clinical trials in Breast cancer (Diagnosis) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top